Company News
Cue Biopharma Phase 2 CSU Yields 54%
Cue Biopharma reported positive Phase 2 results for CUE-221 in chronic spontaneous urticaria trial in China.
The 4 mg/kg dose achieved 54% complete hive resolution at week 12 versus 11% placebo and 41
